Skip to Content

Gleevec Approval History

FDA Approved: Yes (First approved May 10, 2001)
Brand name: Gleevec
Generic name: imatinib mesylate
Dosage form: Tablets
Company: Novartis AG
Treatment for: Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Diseases, Dermatofibrosarcoma Protuberans, Cutaneous Mastocytosis, Gastrointestinal Stromal Tumor

Gleevec (imatinib mesylate) is a kinase inhibitor indicated for the treatment of chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic/ myeloproliferative diseases, mastocytosis, dermatofibrosarcoma protuberans and gastrointestinal stromal tumors.

Development History and FDA Approval Process for Gleevec

DateArticle
Jan 25, 2013Approval FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia
Jan 31, 2012Approval FDA Approves Gleevec for Expanded Use in Patients with Rare Gastrointestinal Cancer
Dec 22, 2008Approval FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide